INTRODUCTION
Most differentiated cells found in mammalian blood have variable but limited life spans and must be constantly replenished. Blood cell homeostasis depends on a rare population of precursor cells, the hematopoietic stem cells (HSCs), which possess the unique capacity for selfrenewal and multilineage differentiation. The function of HSCs and the partially lineage-committed progenitor cells that arise from them has been linked to their migratory properties, at least during fetal life, when the anatomic seat of hematopoietic activity changes several times (Cumano and Godin, 2007) .
In postnatal mammalian life, hematopoietic stem and progenitor cells (HSPCs) reside mostly in specialized niches in bone marrow (BM) cavities that control HSPC survival, proliferation, self-renewal, and differentiation (Adams and Scadden, 2006) . However, even in adulthood, HSPCs are not entirely sessile but contain a population of highly migratory cells. It is well established that some HSPCs recirculate constantly between BM and blood (Goodman and Hodgson, 1962; Wright et al., 2001b) . Accordingly, normal blood from adult mice contains a small but stable population of several hundred HSPCs, which upon transplantation to irradiated recipients are capable of the long-term reconstitution (LTR) of hematopoietic activity (Fleming et al., 1993; Morrison et al., 1997) . It has been speculated that the continuous trafficking of HSPCs between BM and blood is a mechanism to maintain full occupancy of HSPC niches in all BM cavities (Wright et al., 2001b) . However, the exact trafficking pathways of blood-borne HSPCs and the physiological relevance of their postnatal migration remain largely unclear.
The daily turnover of HSPCs that enter and leave the bloodstream is believed to be high (Wright et al., 2001b) . The BM is probably not the exclusive physiological source and destination of blood-borne HSPCs because HSPCs have also been recovered from extramedullary sites, like the liver (Cardier and Barbera-Guillem, 1997) , spleen (Wright et al., 2001b) , and muscle (McKinney-Freeman et al., 2002) . Therefore, although we know little about the migratory dynamics of extramedullary HSPCs, it seems likely that circulating HSPCs visit anatomic regions other than the BM. A case in point is the trafficking of mature lymphocytes, which extravasate continuously into multiple lymphoid and nonlymphoid tissues. Most tissueresident lymphocytes eventually return to the blood via lymphatics that drain into the thoracic duct (TD). This lymphocyte recirculation is essential for immunosurveillance because it maximizes the probability that lymphocytes encounter rare cognate antigens (von Andrian and Mackay, 2000) .
Here, we have examined whether blood-borne HSPCs might follow similar extramedullary traffic patterns as lymphocytes. We demonstrate that efferent lymphatics contain a stable fraction of HSPCs that possess short-and long-term multilineage reconstitution capacity. TD HSPCs originate in the BM and traffic constitutively to multiple extramedullary, nonlymphoid tissues, where they reside for at least 36 hr until entering the draining lymphatics to return to the blood. This recirculation of HSPCs is regulated, in part, by the S1P receptor S1P 1 and might foster the local production of tissue-resident innate immune cells under both steady-state conditions and in response to infections.
RESULTS

Lin
À Hematopoietic Cells Travel in the TD
We surmised that if HSPCs recirculate through extramyeloid tissues, then they, like differentiated lymphocytes, might become lymph borne. Indeed, lymph fluid collected from murine TD (see the Supplemental Experimental Procedures in the Supplemental Data available with this article online) contained up to 4% mononuclear cells (MNCs) that expressed the pan-leukocyte antigen CD45 but no other hematopoietic lineage markers ( Figure 1A ). (Kondo et al., 1997) and common myeloid (CMP) progenitor cells (Akashi et al., 2000) , respectively ( Figure S1 ). 
CD45
+ TD MNCs ( Figure 1A and Figure S1 ). Lymph-derived LSK cells expressed several adhesion and traffic molecules, including CXCR4, CD44, PSGL-1, and LFA-1, as well as a4 and a5 integrins (Table S1 ). Methylcellulose-based colony-forming unit culture (CFU-C) assays of MNCs from blood and TD confirmed that both compartments contain clonogenic HSPCs ( Figure 1B) . Notably, no significant differences were observed in the number of CFU-Cs in peripheral blood collected 6, 12, or 24 hr after surgery or with control blood (without surgery), implying that the collection of thoracic duct lymph per se did not induce the enhanced mobilization of HSPCs (data not shown). Clonogenic cells mostly resided within the Lin À c-Kit + population of TD cells, whereas Lin + or Lin À cKit À TD cells gave rise to no or few colonies in CFU-C assays, respectively ( Figure 1C ). When lymph was collected from irradiated wild-type (WT) mice reconstituted with BM from green fluorescent protein (GFP)-transgenic donors (Wright et al., 2001a) , virtually all of the colonies expressed GFP, indicating that the lymph-borne HSPCs are BM derived ( Figure S2A ). On average, we measured a TD lymph flow of 0.78 ± 0.05 ml/hr, and each ml of lymph contained 4.9 ± 0.8 CFU-C. Considering that TD lymph constitutes only $50% of total body lymph flow, we estimate that $200 clonogenic HSPCs pass through the lymph of a mouse every day. This number is substantial considering the fact that a single HSC can reconstitute the entire hematopoietic system of a mouse and that the infusion of as few as 30 of these cells is sufficient to save 50% of lethally irradiated mice and to reconstitute all blood cell types in the survivors (Spangrude et al., 1988) . Figure S2B ). Multiphoton intravital microscopy of skull BM (Mazo et al., 2005) in anesthetized recipients confirmed that Lin À TD-derived cells can migrate into BM cavities within 12-24 hr after adoptive transfer ( Figure S2C , Movies S1-S3).
Lin
HSPCs with Short-and Long-Term Multilineage Reconstitution Capacity Travel in the TD Lymph So that the functional engraftment capacity of lymphborne HSPCs could be explored, TD MNCs from CD45.2 + donors were transplanted into sublethally irradiated CD45.1 + congenic recipients. After 6 weeks, $15% of Gr-1 + peripheral blood granulocytes were donor derived ( Figure 2A ), indicating that lymph-borne HSPCs possess myeloid differentiation potential (Morrison and Weissman, 1994; Wright et al., 2001b Figure 2C ). Ten weeks after the secondary transplantation, the recipient showed multilineage reconstitution by CD45.2 + cells.
Hence, normal murine lymph contains long-term multilineage repopulating HSPCs that meet the phenotypic and functional criteria of true HSCs.
HSPCs Do Not Require Lymphoid Structures for Recirculation
HSPCs travel between blood and lymph similar to naive lymphocytes. Hence, both populations might share transit routes guiding them from blood into lymphatics. Naive lymphocytes must home to lymph nodes and Peyer's patches (PPs) to gain access to lymph vessels (von Andrian and Mackay, 2000) . Consequently, MNCs were dramatically reduced in lymph of lymphotoxin (LT)-a deficient mice ( Figure 3A ), which lack these lymphoid tissues (De Togni et al., 1994) . However, HSPCs were still present in the TD lymph of LT-a À/À mice, as assessed by fluorescence-activated cell sorting (FACS) (data not shown) or CFU-C assays ( Figure 3B ). Thus, HSPCs, unlike lymphocytes, do not require secondary lymphoid organs (SLOs) to recirculate but might traffic directly to the lymph from extramedullary nonlymphoid tissues.
HSPCs Continuously Travel from the BM to Various Extramedullary Tissues
To define where and how HSPCs might leave the blood and pass through extramedullary tissues into the lymph, we first surveyed different murine tissues for the presence of HSPCs by using CFU-C assays. Clonogenic progenitors were detectable in many tissues, including the lung, liver, small intestine, kidneys, and blood, but CFU-Cs were rare or absent in cardiac and skeletal muscle, skin, and LNs ( Figure S3 ). It should be noted that we counted the number of colonies 7 days after the plating of the cells in methylcellulose to detect primitive HSPCs with large burst size. Therefore, our data do not account for the presence of late-outgrowth (more committed) progenitors, that have been reported to reside within some tissues, including peripheral LNs (MacVittie and McCarthy, 1977) . Virtually all clonogenic tissue HSPCs were BM derived because colonies uniformly expressed GFP in chimeric wild-type recipients of GFP + BM (data not shown). Moreover, the transplantation of liver-derived CFU-Cs into irradiated recipients resulted in multilineage reconstitution, indicating that at least in some organs, clonogenic cells possess multilineage reconstitution capacity (data not shown). On the basis of the yield of CFU-Cs in surveyed organs, we estimate the total number of HSPCs resident in extramedullary nonlymphoid tissue to be at least twice as large as the average number of HSPCs circulating in murine blood (Wright et al., 2001b) . Next, we generated pairs of parabiotic mice, in which one partner ubiquitously expressed GFP. Consistent with previous reports (Wright et al., 2001b) , crosscirculation was established by day 3 after surgical joining, and the host:partner (i.e. GFP + :GFP À ) ratio of both mature leukocytes and CFU-C in blood plateaued at $3:2 (corresponding to 40% chimerism) between days 10 and 14 (data not shown). In contrast, CFU-C chimerism in the BM reached only $5% after 14 days of parabiosis ( Figure 4A ). Similar levels of BM chimerism were reported in mice joined for up to 16 weeks . In extramedullary tissues of parabiotic mice, the highest level of HPC chimerism was in the spleen (40 ± 7%), and then the lungs (31 ± 6%), liver (24 ± 9%), and kidneys (15 ± 5%), implying that within these organs, tissue-resident HSPCs are constantly replenished by blood-borne HSPCs and are turned over within a matter of days. Partner-derived CFU-Cs were undetectable in the small intestine or brain. We also detected marked CFU-C chimerism (27 ± 1%) in the lymph of parabiotic mice, indicating that at least some homed HSPCs are not permanently retained in extramedullary tissues but recirculate freely between lymph and blood ( Figure 4B ).
To define the kinetics at which HSPCs enter the lymph after having accessed extramedullary tissues, we surgically separated some pairs of mice after 14 days of parabiosis. After separation, blood chimerism decreased rapidly, whereas lymph-borne HSPC chimerism was unchanged during the first 36 hr and declined only thereafter ( Figure 4C ). Given this delayed drop in HSPC chimerism, we estimate that the mean dwell time of HSPCs that have homed to peripheral tissues is at least 36 hr. This suggests that many organs are sites of active HSPC traffic from blood to tissue to lymph, but certain organs recruit few, if any, circulating HSPCs, at least over the 2 week time interval tested. Of note, a tracer (1% Evans Blue) injected directly into femur BM did not appear in any juxtaposed LN (data not shown) but became rapidly visible in draining LNs after intracutaneous injection. This is consistent with the long-held notion that mammalian BM lacks lymphatic drainage. Thus, HSPCs in the BM egress directly into the blood, whereas lymph-borne HSPCs have most likely departed from tissues other than the BM.
Sphingosine 1-Phosphate Receptor S1P 1 Regulates the Egress of HSPCs from Tissues into Lymphatics Next, we sought to determine whether chemoattractants guide HPC recirculation. Most chemoattractants that control leukocyte migration signal through Gai-coupled receptors that can be inhibited by pertussis toxin (PTX). Indeed, as early as 2-12 hr after a single PTX injection, we observed a dramatic drop in the number of lymph-borne CFU-Cs ( Figure 5A ). In blood, the number of CFU-Cs was not significantly altered during this time interval; however, their number increased markedly at 24-96 hr after PTX injection (Papayannopoulou et al., 2003 ; data not shown). Thus, Gai-coupled chemoattractants might play a role in the long-term recruitment of HSPCs from blood to tissues. However, our parabiosis experiments predict that the dwell time of HSPCs within tissues is greater than 36 hr. This implies that a PTX-induced drop in 
Figure 5. Egress of HSPCs from Extramedullary Tissues into Lymph is PTX Sensitive and Depends on S1P
(A) Effect of PTX on lymph-borne CFUc. Lymph was collected for 8 hr from mice that were previously treated for 2 hr with vehicle or 1 mg PTX, and CFU-C concentration was measured. n = 4-6 assays.
(B) Effect of FTY720 on lymph-borne MNCs and CFUc. The effect of treatment with S1P receptor antagonist FTY720 (6 hr) on MNC concentration (left panel, n = 4-7) and CFU-C content (right panel, n = 12-14) in lymph is shown.
(C) Effect of FTY720 in LTx-a À/À mice. CFU-C assays were performed with thoracic duct MNC collected from LT-a-deficient mice treated with vehicle or FTY720. Lymph MNCs were collected for 8 hr from FTY720-pretreated mice starting at 6 or 48 hr after the last drug administration. The number of CFU-Cs per ml of lymph is shown.
lymph-borne CFU-Cs should only become manifest after $36 hr if migration across the blood-tissue interface is the only step affected by PTX. The much more rapid time course of PTX-induced CFU-C disappearance from lymph implies an essential role for a Gai-coupled signal that directs tissue-resident HSPCs into draining lymphatics. Egress of tissue-resident lymphocytes into lymphatics is controlled by S1P 1 , a Gai-coupled receptor for sphingosine 1-phosphate (S1P) (Massberg and von Andrian, 2006; Rosen and Goetzl, 2005) . We found that murine HSPCs express S1P 1 , as well as S1P 2 , S1P 3 , and S1P 4 messenger RNA (mRNA) ( Figure S4A ). Although quantitative real-time polymerase chain reactin (PCR) showed that the S1P 1 mRNA expression levels are lower on HSPC subsets compared to B and T cells ( Figure S4B ), they were much higher than on myeloid cells, and both progenitor subsets migrated toward S1P in vitro ( Figure S4C ). Thus, we asked whether S1P signaling might influence HSPC recirculation. Most S1P receptors, including S1P 1 , are blocked by the immunosuppressant FTY720, which induces lymphocyte sequestration in SLOs, causing profound lymphopenia in blood and lymph (Chiba et al., 1998; Mandala et al., 2002; Matloubian et al., 2004) . Remarkably, the treatment of mice with FTY720 for 6 hr nearly abolished lymph-borne CFU-Cs ( Figure 5B ). Among the multiple S1P receptors expressed by HSPCs, S1P 1 appeared to play the predominant role for this effect because SEW2871, which selectively targets S1P 1 , transiently reduced the appearance of lymph-borne CFUCs to a similar extent as FTY720 ( Figure S4D ). The disappearance of lymph-borne CFU-Cs in response to S1P receptor inhibition did not require HSPC sequestration in SLOs because FTY720 blocked HSPC recirculation also in LT-a À/À mice ( Figure 5C ). HSPCs reappeared in the lymph of LT-a À/À mice within 2 days after the discontinuation of FTY720 treatment ( Figure 5C ), suggesting that FTY720 does not affect the viability of HSPCs. Likewise, FTY720 did not alter the capacity of HSPCs to form colonies in CFU-C assays (data not shown). Notably, FTY720 not only depleted lymph-borne HSPCs but also induced a significant (74 ± 5%) drop of CFU-Cs in the blood ( Figure 5D ). On the basis of our parabiosis experiments, a decrease of HSPC migration across the blood-tissue interface would translate into a decrease in lymph CFU-Cs only after $2 days. This suggests that the drop of blood CFU-Cs alone cannot account for the disappearance of CFU-Cs from the lymph observed within 6 hr after FTY720 treatment. The treatment of mice with FTY720 over 7 days resulted in a significant increase in the number of HSPCs residing within extramedullary tissues ( Figure 5E ). Hence, our data imply that S1P receptors, particularly S1P 1 , regulate the egress of HSPCs from tissue into the draining lymphatic vasculature. The number of HSPCs in the BM of FTY720-treated mice was not significantly altered compared to vehicle-treated animals ( Figure S4E) . Hence, the FTY720-induced disappearance of HSPCs from blood was due to the inhibition of HSPC recirculation from extramedullary tissues. Consistent with this notion, we did not observe a significant difference in the number of HSPCs mobilized to the blood in response to G-CSF between mice treated with FTY720 or vehicle (data not shown). S1P is abundant in blood and lymph but low in lymphoid and nonlymphoid tissues because of rapid interstitial degradation by tissue-resident S1P lyase (Schwab et al., 2005) . Extravascular lymphocytes in LNs enter the lymph in response to steep S1P gradients. This egress step can be inhibited by the pharmacological blockade of S1P lyase with 2-acetyl-4-tetrahydroxybutylimidazole (THI) (Schwab et al., 2005) . To test whether S1P degradation through S1P lyase is also required for HSPC recirculation, we collected lymph from THI-treated mice. As reported previously (Schwab et al., 2005) , THI treatment resulted in profound lymphopenia in blood and lymph (data not shown). Concomitantly, lymph-borne HSPCs were markedly reduced ( Figure 5F ), indicating that S1P lyase is required for HSPC passage through tissues. Figure 6A ) but also within the blood and the BM, as assessed by CFU-C assay after the implantation of Lin 6B ). These cells were typically located in clusters, each comprising up to $400 cells. Similar findings were obtained when we instilled LPS beneath the kidney capsule immediately prior to the implantation of HSPCs that were not previously incubated with LPS ( Figure 6A Figure S5C ). A small subset ($10%) of GFP + cells expressed Gr-1 at intermediate to high levels, indicative of monocyte and/or macrophage and/or granulocyte differentiation, whereas very few (<1%) GFP + myeloid cells were stained with 120G8 mAb, which recognizes plasmacytoid dendritic cells (Figures 6D and 6E, Figure S5C , and data not shown). Most of the GFP + clusters contained either CD11c + or Gr-1 + cells, and < 10% of the clusters contained a mixture of both subsets. A sizeable fraction (>15%) of GFP + cells expressed neither CD11c nor Gr-1, suggesting that some cells remained either undifferentiated or gave rise to other leukocyte subsets.
In all instances, the numbers of all GFP + cells and of myeloid GFP + cells were significantly higher after the implantation of HSPCs together with LPS compared to kidneys injected with the same subset of GFP + HSPCs without LPS (Figure 6A ), suggesting their local proliferation after TLR ligand engagement. When recipient mice were treated with bromodeoxyuridine (BrDU) after the implantation of HSPC-enriched GFP + cells, the majority of the cells of each of the GFP + clusters had incorporated BrDU into their nucleus ( Figure 6F ). Similar findings were obtained when clusters were stained for the proliferation marker Ki-67 ( Figure 6F ), implying that in the presence of TLR ligands HSPCs proliferate locally. The engagement of LPS also reduced the exit of clonogenic HSPCs out of peripheral tissues because the number of donor-derived GFP + CFU-Cs was significantly reduced in both peripheral blood and BM after the implantation of LPS-pretreated cells ( Figure 6C ). Along these lines, the number of GFP + cells in the control kidneys (injected with medium or LPS without cells), was significantly higher in mice injected with medium as compared to LPS-treated mice. Although the overall number of donor-derived cells was low in the control kidneys injected with LPS without HSPCs, we detected GFP + Ki-67 + myeloid clusters in these kidneys ( Figure 6F ), providing additional in vivo evidence for the concept of HSPC migration to peripheral tissues contributing to myeloid defense in inflamed organs.
LPS Interferes with S1P-S1P 1 Signaling in Recirculating HSPCs
Finally, we asked whether TLR stimulation might modulate the capacity of HSPCs to migrate toward S1P gradients. We sorted Lin À or Lin to LPS, had 2-to 3-fold-reduced S1P 1 transcript levels ( Figure 7A , p < 0.05). The downregulation of S1P 1 in response to LPS was paralleled by the failure of LPS-treated HSPCs to chemotax toward gradient of S1P, whereas migration toward CXCL12/SDF-1a was enhanced ( Figure 7B ). Hence, LPS recognition not only triggers local proliferation and differentiation but also leads to the retention of HSPCs within extramedullary tissues ( Figure 6C ), at least in part by interfering with S1P-S1P 1 -dependent signaling.
DISCUSSION
Our data suggest that extramedullary tissues are constitutively surveyed by a pool of recirculating hematopoietic progenitors that are highly versatile and can respond rapidly to distress signals from the local microenvironment ( Figure 7C ). Naive T and B lymphocytes, another population of recirculating cells, gain access to the lymphatic vasculature after homing to SLOs, which they reach through specialized postcapillary venules, the high endothelial venule (HEV) (von Andrian and Mackay, 2000) . However, HSPCs can be recovered from TD lymph of lymphotoxin-a-deficient mice that lack HEVs and SLOs (De (B) Lin À BM-derived cells pretreated for 12 hr with LPS or medium were tested for their ability to migrate to 100 nM S1P or to 50 nM CXCL12/SDF-1a.
Migration to the lower chamber was determined by flow cytometry and is given as percentage of the number of input cells (n = 3 experiments per group). ''*'' indicates p < 0.05 versus SDF-1a. Results are shown as mean ± SEM.
(C) Schematic model illustrating the trafficking of migratory HSPCs under physiological conditions and during an inflammation (for details, see main text). Togni et al., 1994) . This implies that blood-borne HSPCs do not require SLOs to access lymphatics. Accordingly, we recovered few, if any, CFU-Cs from pooled LNs. Although HSPCs entering the lymph in peripheral nonlymphoid tissues must pass through at least one draining LN before reaching the TD, lymph-borne HSPCs that give rise to early CFU-Cs (within 7 days of culture) are apparently not retained in the LN stroma but continue to travel through efferent lymph conduits into the blood. This lack of HSPC accumulation in LNs is most likely due to the fact that HSPCs lack CCR7 (Wright et al., 2002) , which is essential for homing to LNs (Debes et al., 2005; Forster et al., 1999; Stein et al., 2000) . However, HSPCs express multiple other traffic molecules, including PSGL-1, VLA-4 (CD49d/CD29), LFA-1 (CD11a/CD18), CD44, and the chemokine receptor CXCR4, which are likely to contribute to HSPC migration to nonlymphoid tissues, particularly sites of inflammation (Table S1 ) (Wright et al., 2002) . Although the recruitment mechanism(s) responsible for HSPC trafficking from blood into extramyeloid tissues remain(s) to be elucidated, our experiments have uncovered a pivotal role for S1P during the subsequent departure of tissue-resident HSPCs into lymphatics. S1P plays a key role in enabling lymphocyte egress from the thymus into the blood and from SLOs into the lymph (Cyster, 2005; Massberg and von Andrian, 2006; Rosen and Goetzl, 2005) . Our study demonstrates that S1P and its receptors, in particular S1P 1 , also regulate HSPC recirculation. HSPCs disappeared from blood and TD lymph when WT or lymphotoxin-a-deficient mice were treated with FTY720. In principle, this effect would be expected with any treatment that blocks HSPC trafficking from one compartment to another, be it from the BM to the blood, from blood to extramyeloid tissues, or from tissues into the lymph. However, our parabiosis experiments revealed that HSPCs need at least 36 hr to transit from the blood across peripheral tissues into the draining lymph, so treatment effects that block HSPC homing from blood to tissues would only result in reduced lymph-borne CFU-Cs after this lag time. In contrast, both SEW2871 and FTY720 treatment depleted HSPCs from the lymph within only 6 hr, indicating that S1P, acting primarily through S1P 1 , controls HSPC exit from nonlymphoid tissues into the draining lymph vessels. This interpretation is also consistent with the observation that prolonged FTY720 treatment resulted in HSPC accumulation in peripheral tissues, whereas the number of blood-borne HSPCs was reduced. Because HSPCs express S1P 1 mRNA and chemotax toward S1P gradients in vitro ( Figures S4A-S4C and Figure 7) , it is likely that HSPC-expressed S1P 1 mediates HSPC egress from extramedullary tissue. However, it should be noted that lymphatic endothelial cells also express S1P 1 (Singer et al., 2005; Wei et al., 2005) , which raises the possibility that S1P might exert additional control over HSPC trafficking via its action on lymphatic endothelial cells.
An S1P gradient between lymphoid tissue and lymph fluid is required for lymphocyte egress from LN (Schwab et al., 2005) . Interstitial tissue fluids contain low levels of S1P, whereas extracellular S1P concentrations in lymph and plasma are high (Cyster, 2005; Schwab et al., 2005) . Although plasma S1P is mainly produced by hematopoietic cells, high lymph S1P levels are maintained by a nonhematopoietic, radiation-resistant source (Pappu et al., 2007) . The S1P gradient between LNs and lymph fluid is maintained by the S1P-degrading enzyme S1P lyase (Schwab et al., 2005) , which is abundant in most tissues and cell types except in platelets and erythrocytes (Pappu et al., 2007) . Our present findings suggest that S1P lyase is similarly essential for the egress of HSPCs from nonlymphoid extramedullary tissues. S1P gradients are also required for the migration of bilateral heart progenitors in zebrafish (Kupperman et al., 2000) . Hence, guidance signals provided by extracellular lipids, such as S1P, might represent a conserved navigation mechanism for migrating stem and progenitor cell populations that is utilized by vertebrates and invertebrates alike.
What is the functional relevance of HSPC trafficking in adults? The recirculation of HSPCs between the BM and blood is believed to be important for the maintenance of hematopoietic homeostasis in dispersed BM cavities (Wright et al., 2001b) . However, the role of the migratory pool of HSPCs that percolate constitutively through extramedullary tissues and then return to the blood via the TD is less obvious. Our kidney capsule transplantation experiments show that even in the absence of inflammation, recirculating HSPCs divide locally in peripheral tissues and differentiate into mature myeloid cells. Homed HSPCs might thus help to constitutively replenish the diverse population of tissue-resident leukocytes that perform multiple essential functions in peripheral organs, including, e.g., the removal of dead cells and debris.
Given the diverse activities of leukocytes in the context of tissue damage and immune defense, it would seem plausible that HSPCs might possess the ability to sense and respond to situations, such as tissue damage and infections, that require the rapid influx of large numbers of innate immune cells. Indeed, HSPCs express TLR2 and TLR4 (Nagai et al., 2006) , which sense pathogenassociated molecular patterns, such as peptidoglycan and lipoteichoic acid from Gram-positive bacteria and LPS from Gram-negative bacteria, respectively (Hoshino et al., 1999) . It was shown in vitro that the incubation of both primitive and committed HSPCs with TLR ligands triggers HSPC proliferation and rapid myeloid differentiation. On the basis of this discovery, it was hypothesized that this mechanism could provide a means for boosting innate immunity during life-threatening infections, where microbial components either access the circulation and reach the BM or where dispersed stem and progenitor cells sense foreign materials outside the marrow compartment and become locally converted to innate effector cells (Nagai et al., 2006) . In fact, we show the existence of a migratory pool of HSPCs that constitutively survey peripheral tissues. Our experiments indicate that once these cells sense microbial danger signals, they proliferate vigorously and boost the local supply of innate effector cells. Thus, the migratory pool of HSPCs might act as a source of highly versatile stem and progenitor cells that can respond to danger signals locally within tissues before the information has spread to the BM. Notably, TLR stimulation also blocks HSPC egress from inflamed tissues and abolishes HSPC chemotaxis to S1P in vitro. Hence, TLR-induced changes in S1P receptor expression regulate the dwell time of HSPCs in inflamed tissues and thereby act as a rheostat that can boost local leukocyte generation.
In conclusion, we show here that HSPCs constitutively survey extramedullary nonlymphoid tissues. Our results raise the possibility that in the absence of infection, migratory HSPCs contribute to the continuous restoration of specialized hematopoietic cells that reside in peripheral tissues. During tissue infection, the migratory pool of HSPCs might act as an immediate and highly adaptive source of progenitor cells that proliferate locally and generate innate immune effector cells. It will be important to determine how HSPC traffic within peripheral tissues is influenced by and might modulate the course of infectious diseases and of other acute or chronic inflammatory conditions.
EXPERIMENTAL PROCEDURES
Thoracic Duct Cannulation Thoracic duct cannulation was performed as described previously (Ionac, 2003) . Where indicated, mice were treated with PTX (50 mg/kg iv, 2 hr prior to cannulation), FTY720 (1 mg/kg ip, 6 hr prior to cannulation), SEW2871 [20 mg/kg 6 hr prior to cannulation (Wei et al., 2005) ], or THI (drinking water with 10 g/L glucose plus 50 mg/ml THI for 3 days prior to cannulation).
Parabiosis
Six-to eight-week-old sex-and age-matched C57BL/6 WT and b-actin/GFP mice (Wright et al., 2001a) were joined at the flanks as described (Wright et al., 2001b) . Where indicated, mice were surgically separated prior to the collection of TD lymph. the cells were preincubated with medium containing stem cell factor (R&D, 20 ng/ml), Flt-3 ligand (R&D, 100 ng/ml) in the absence or presence of LPS (Sigma, 10 mg/ml), and CD14-Fc (R&D, 1 mg/ml) for 12 hr before implantation or were not pre-exposed to LPS but injected into the kidneys together with LPS (10 mg/ml). The right kidney was used as a control and was injected with medium with or without LPS (Sigma, 10 mg/ml) and CD14-Fc (R&D, 1 mg/ml). Where indicated, the recipient mice received 1 mg/day BrDU i.p (BD Biosciences [San Jose, CA]) on days 4, 5, and 6 after implantation. Six days after the implantation of the cells, mice were perfusion fixed and the kidneys were harvested and quantitatively analyzed by confocal laser scanning microscopy. To this end, five serial sections (each 30 mm thick) were obtained from the anterior aspect of the kidney and stained with fluorescently tagged anti-GFP (Rockland [Gilbertsville, PA]), anti-CD45, anti-CD45.1, anti-CD45.2, anti-Gr-1(Ly6G/C), anti-CD11c, anti-B220, anti-CD3 (all from BD Biosciences), mouse anti-human Ki-67 antibody (B56, crossreacting with mouse Ki-67, BD Biosciences) and anti-pDC/ IPC (clone 120G8.04, Dendritics [France]) as indicated. So that myeloid differentiation could be detected, sections were stained with a panel of monoclonal antibody (mAb) against myeloid lineage markers [CD11b, CD11c, F4/80, Gr-1(Ly6G/C)] and then APC-conjugated streptavidin (BD Biosciences). BrDU in situ detection was performed according to the manufacturer's recommendations with biotin-labeled antibody recognizing BrDU (BrDU in situ detection kit, BD Biosciences) and APC-conjugated streptavidin (BD Biosciences).
Colony-Forming Unit Assays
Statistical Analyses
Quantitative results are expressed as means ± the standard error of the mean (SEM) unless otherwise indicated. The Mann-Whitney test was used for the determination of the significance of differences between means. Statistical significance was assumed at p < 0.05.
Supplemental Data
Supplemental Data include Experimental Procedures, five figures, one table, and three movies and can be found with this article online at http://www.cell.com/cgi/content/full/131/5/994/DC1/.
